Evaluation of pegaptanib and ranibizumab for macular edema secondary to retinal vein occlusion

Evaluation of pegaptanib and ranibizumab for macular edema secondary to retinal vein occlusion - Evaluation of pegaptanib and ranibizumab for macular edema secondary to retinal vein occlusion

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002012

Enrollment

Registered

2010-04-30

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

macular edema secondary to retinal vein occlusion

Interventions

Intravitreal pegaptanib for treatment Intravitreal ranibizumab for treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with macular edema secondary to retinal vein occlusion and with visual acuity less than 0.5

Exclusion criteria

Exclusion criteria: The patients with good visual acuity

Design outcomes

Primary

Measure	Time frame
visual acuity,foveal thickness	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026